Company news
Abera Bioscience Ab (NGM:ABERA) news
Abera Bioscience Ab news releases on 6ix. Latest, May 12, 2026: ABERA: 7% organic growth and stable margins in Q1 2026, with strong energy and infrastructure…
Press releases & updates
ABERA: 7% organic growth and stable margins in Q1 2026, with strong energy and infrastructure demand
May 12, 2026
ABERA: Transition to clinical-stage vaccines, strong financing, and expanded R&D drive future growth
February 12, 2026
ABERA: Secured funding and positive R&D milestones drive clinical progress despite ongoing losses
November 13, 2025
ABERA: Positive preclinical results and new funding drive clinical trial preparations and liquidity
August 21, 2025
ABERA: Positive Q1 2025 result and strong vaccine pipeline progress, supported by grants
May 13, 2025
ABERA: Strong grants and preclinical results position Abera for growth in mucosal vaccines
February 13, 2025
ABERA: Q3 2024 saw grant-driven revenue, reduced losses, and pipeline expansion for Abera Bioscience
November 13, 2024
ABERA: Net loss narrowed and vaccine pipeline advanced as new lab and funding boosted operations
August 21, 2024